Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5360300 | 0.88 | GAA (0.48) | GAAALDH1A1GFERCYP4F2CYP4A11 | |
| SCHEMBL30154495 | 0.88 | GAA (0.48) | GAAALDH1A1GFERCYP4F2CYP4A11 | |
| SCHEMBL12985044 | 0.85 | MAPT (0.42) | GAAALDH1A1CACNA1HMAPTKDM4E | |
| SCHEMBL19899947 | 0.85 | RAB9A (0.46) | GAAALDH1A1MAPTKDM4ECYP1A2 | |
| SCHEMBL2988579 | 0.84 | CACNA1H (0.45) | ALDH1A1CYP4F2CYP4A11CACNA1HGLA | |
| SCHEMBL13665106 | 0.83 | GAA (0.60) | GAAALDH1A1GFERCYP4F2CYP4A11 | |
| SCHEMBL20045089 | 0.83 | GAA (0.49) | GAAALDH1A1GFERCYP4F2CYP4A11 | |
| SCHEMBL23832277 | 0.82 | GAA (0.48) | GAAALDH1A1GFERCYP4F2CYP4A11 | |
| SCHEMBL5739424 | 0.82 | ALDH1A1 (0.55) | GAAALDH1A1GFERCYP4F2CYP4A11 | |
| SCHEMBL13610493 | 0.82 | GAA (0.59) | GAAALDH1A1GFERCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110143945-A | A kind of simple and convenient process for preparing of 4- substituent group methyl-1-(2H) phthalazone | 新发药业有限公司 | 2019-08-20 | — | — | CN | disclosed |
| US-8362056-B2 | 4-heteroaryl-substituted phenoxyphenylacetic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2455105-A2 | Bombesin analogues | Bayer Pharma Aktiengesellschaft (DE) | 2012-05-23 | — | — | EP | disclosed |
| EP-2289564-A2 | Derivatives of aniline as precursors for F18-labeling | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-03-02 | — | — | EP | disclosed |
| EP-2279759-A2 | Compounds and methods for 18F labeled agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-02-02 | — | — | EP | disclosed |
| US-20100273850-A1 | 4-HETEROARYL-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | ARRAY BIOPHARMA, INC. | 2010-10-28 | — | — | US | disclosed |
| WO-2009061730-A2 | 4-HETEROARYL-SUBSTITUTED PHENOXYPHENYLACETIC ACID | ARRAY BIOPHARMA INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20080292548-A1 | COMPOUNDS AND METHODS FOR 18F LABELED AGENTS | Lantheus Biosciences Ltd. (GB) | 2008-11-27 | — | — | US | disclosed |
| EP-1985624-A2 | Single step method of radiofluorination of biologically active compounds or biomolecules | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-10-29 | — | — | EP | disclosed |
| WO-2008028688-A2 | COMPOUNDS AND METHODS FOR 18F LABELED AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273850-A1 | 4-HETEROARYL-SUBSTITUTED PHENOXYPHENYLACETIC ACID DERIVATIVES | CD22, HRH2, PTGDR2 | GAA 2244/4885ALDH1A1 348/4885GFER 3126/4885 |
| US-20080292548-A1 | COMPOUNDS AND METHODS FOR 18F LABELED AGENTS | QPCT, GBA2, GBA1 | GAA 37/4885ALDH1A1 2019/4885GFER 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.